Treatment With SAB-185 Is Safe, Results In Faster Symptom Resolution Compared With Casirivimab-Imdevimab Among Patients Infected With Omicron Variant Of COVID-19, Study Finds

Infectious Disease Advisor (8/23, Nye) reported, “Among patients infected with the Omicron variant of COVID-19, treatment with SAB-185 is safe and results in faster symptom resolution when compared with casirivimab-imdevimab, according to study findings.” Investigators also observed that “median time to 2 consecutive days of sustained symptom improvement was shorter among patients in the pre-Omicron population who received SAB-185 (11 vs 14 days; P =.95).” The findings were published in the Journal of Infectious Diseases.